InVentis Technologies to Distribute TriLink Products in India
News Nov 07, 2014
TriLink BioTechnologies, Inc. has entered into a distribution agreement with inVentis Technologies, an Indian distribution and manufacturing company specializing in the life science and applied science, research, diagnostics and QC market. The agreement allows inVentis to market TriLink’s complete line of nucleic acid-based products. This includes TriLink’s stocked and custom nucleotides, oligonucleotides and mRNA, as well as their CleanAmp™ Hot Start PCR Products.
"With the biotech industry growing rapidly in India, TriLink has been looking for the right opportunity to enter the market. InVentis provides an extensive line of life science products to the biotech and pharmaceutical market and we feel that our high quality nucleic acid-based products will complement their offering and help advance research in the area,” commented TriLink's President and CEO, Richard Hogrefe, Ph.D.
“With the biotechnology industry in India increasingly focused on “OMICS”, InVentis has been looking for a world-class nucleic acid-based product line to fulfill the growing demand in the genomics and molecular biology sector. We anticipate that the market will continue to grow and addition of TriLink products will complement the portfolio offered by InVentis”, stated Founder and BM Singh, Sandeep. “We are delighted to enter into an agreement with TriLink.”
Giant Viruses Invent Their Own GenesNews
Three new members have been isolated and added to the Pandoravirus family. This strange family of viruses, with their giant genomes and many genes with no known equivalents, surprised scientists when they were discovered a few years ago. This new study notes that pandoraviruses appear to be factories for new genes – and therefore new functions.
Therapeutic CRISPR Could Be Cancer RiskNews
Therapeutic use of gene editing with the so-called CRISPR-Cas9 technique may inadvertently increase the risk of cancer, according to a new study. Researchers say that more studies are required in order to guarantee the safety of these ‘molecular scissors’ for gene-editing therapies.